Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
0
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
https://www.zacks.com/stock/news/2245553/bayer-bayry-banks-on-pipeline-progress-amid-challenges?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245553
Mar 25, 2024 - Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
0
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
https://www.zacks.com/stock/news/2253861/will-novavax-s-nvax-strategic-reshaping-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253861
Apr 11, 2024 - To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
0
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
https://www.zacks.com/stock/news/2253860/will-pfizer-s-pfe-new-drugs-provide-a-boost-to-2024-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253860
Apr 11, 2024 - Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
It's Jobs Week Already? Plus Q4 Reports from MSFT, GOOGL, AAPL, AMZN
https://www.zacks.com/stock/news/2217145/it-s-jobs-week-already-plus-q4-reports-from-msft-googl-aapl-amzn?cid=CS-ZC-FT-ahead_of_wall_street-2217145
Jan 29, 2024 - This week starts slow, but we'll end it with a full-fledged Jobs Week for February. Plus more than half the Magnificent 7 reports earnings.
0
Big Earnings Week Ahead
https://www.zacks.com/stock/news/2217255/big-earnings-week-ahead?cid=CS-ZC-FT-economic_highlights-2217255
Jan 29, 2024 - Big Earnings Week Ahead
0
The Bull Market Left These 3 Stocks Behind, but They're Buys Right Now
https://www.fool.com/investing/2024/02/04/the-bull-market-left-these-3-stocks-behind-but-the/?source=iedfolrf0000001
Feb 04, 2024 - Sometimes, undervalued market laggards have what it takes to catch up over the long haul.
0
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run
https://www.fool.com/investing/2024/03/10/have-2000-2-magnificent-stocks-ready-for-a-bull-ru/?source=iedfolrf0000001
Mar 10, 2024 - These stocks are trading down, but investors may be overlooking some important points.
0
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
0
<Page 2